Market Cap | 60.41M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -70.45M | Forward P/E | -1.93 | EPS next Y | 42.30% | 50D Avg Chg | -16.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -25.00% |
Dividend | N/A | Price/Book | 1.21 | EPS next 5Y | - | 52W High Chg | -75.00% |
Recommedations | 2.00 | Quick Ratio | 5.11 | Shares Outstanding | 759.69M | 52W Low Chg | 38.00% |
Insider Own | 6.66% | ROA | -44.21% | Shares Float | 322.71M | Beta | 0.96 |
Inst Own | 24.94% | ROE | -79.36% | Shares Shorted/Prior | 23.46M/23.05M | Price | 0.29 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,380,248 | Target Price | 7.00 |
Oper. Margin | - | Earnings Date | - | Volume | 5,956,213 | Change | -8.52% |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Roth Capital | Buy | Apr 28, 21 |